Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
26.29 | 42.56 | 48.61 | 30.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(40.82) | (25.53) | (29.08) | (12.22) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
17.43 | 28.29 | 22.94 | 8.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.77) | (6.34) | (2.64) | (1.39) | |
EV/FCF |
(5.73) | (6.30) | (2.63) | (1.39) | |
Quick Ratio |
11.88 | 11.70 | 9.01 | 12.85 | |
Current Ratio |
12.14 | 11.91 | 9.22 | 13.15 | |
Net Debt/EBITDA |
9.89 | 10.29 | 7.09 | 7.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.06 | 0.05 | 0.05 | |
Operating CF/Net income |
(0.23) | 0.10 | 0.04 | 0.13 | |
Capex/Depreciation |
(0.37) | (1.85) | (1.31) | (0.39) | |
Research and Development Expense of Revenue |
169.68% | 186.56% | 1,702.84% | 790.84% | |
Selling, General and Administrative Expense of Revenue |
137.72% | 122.56% | 790.91% | 416.48% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
57.86% | 42.10% | 189.77% | 102.24% | |
Graham Net Nets |
(0.74) | (0.89) | (1.15) | (0.29) | |
Graham Number |
125.59 | 146.58 | 137.30 | 37.14 | |
Earnings Yield |
(144.08%) | (129.04%) | (147.65%) | (173.31%) | |
Free Cash Flow Yield |
(11.56%) | (10.56%) | (17.97%) | (19.04%) | |
Revenue per Share |
0.43 | 0.46 | 0.07 | 0.11 | |
Operating CF per Share |
(0.64) | (1.14) | (0.78) | (1.05) | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.64) | (1.15) | (0.79) | (1.06) | |
Cash per Share |
8.75 | 9.76 | 11.93 | 9.49 | |
Shareholders Equity per Share |
(18.75) | (25.40) | (25.11) | (2.74) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(18.75) | (25.40) | (25.11) | (2.74) | |
Free Cash Flow |
(7.43) | (12.61) | (5.87) | (9.06) | |
Working Capital |
100.39 | 104.38 | 81.63 | 79.33 | |
Capital Expenditures |
(0.02) | (0.12) | (0.06) | (0.02) | |
Net Current Asset Value |
(224.87) | (284.91) | (194.93) | (31.70) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.11 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.78 | 3.82 | 1.37 | 7.38 | |
Average Payables |
0.71 | 0.60 | 0.52 | 0.41 | |
Average Assets |
109.15 | 117.77 | 73.60 | 71.02 | |
Average Common Equity |
(85.78) | (136.24) | (104.57) | (8.92) |
Columns are period end dates